Sign In
Buy RNA
$11.35
-0.110 (-0.96%)
At Close: Jul 31, 2026
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates
07:52pm, Tuesday, 09'th May 2023
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.71 per share a year ago.
Avidity (RNA) Down on Update From Neuromuscular Disease Study
01:04pm, Friday, 31'st Mar 2023
Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy type I. The stock falls about 17%.
Avidity Bio Crashes 26% After 'Rarer Than Rare' Event Sidelines Key Study
09:20am, Thursday, 30'th Mar 2023
A key study from Avidity Biosciences remains on hold after a patient experienced a rare side effect, leading RNA stock to plummet Thursday. The post Avidity Bio Crashes 26% After 'Rarer Than Rare' Eve
Avidity's stock falls after sharing additional data about partial clinical hold
07:52am, Thursday, 30'th Mar 2023
Shares of Avidity Biosciences Inc. RNA, +0.55% fell about 3.0% in premarket trading on Thursday after the company said a partial clinical hold on its experimental treatment for adults with myotonic dy
Avidity Biosciences: Helping Deliver Oligonucleotides Outside Liver Cells
03:03pm, Thursday, 09'th Mar 2023
Avidity Biosciences, Inc. is a leader in antibody Oligonucleotide conjugate technology. This technology enables delivery of Oligonucleotides to muscles and other tissues.
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
09:05pm, Tuesday, 28'th Feb 2023
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -4.76% and 15.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the s
5 Best and Worst Performing Small-Cap Stocks in Dec 2022
10:59pm, Tuesday, 17'th Jan 2023
Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.
Avidity Biosciences Will Rise As It Revolutionizes The Field Of RNA Therapeutics
07:12am, Friday, 23'rd Dec 2022
Avidity Biosciences possesses the only RNA agent capable of being delivered into the muscle. The company's platform success opens up its pipeline to rare muscle diseases and previously unreachable tis
Avidity Biosciences: Unique Antibody-Oligonucleotide Conjugate Technology
05:22am, Thursday, 22'nd Dec 2022
Avidity Biosciences' stock was up 55% last week after releasing preliminary data from a Phase 1/ 2 study of its antibody-oligonucleotide technology candidate in treating myotonic dystrophy type 1. The
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
01:44pm, Wednesday, 14'th Dec 2022
Business wins are shining the spotlight on these two companies.
RNA Breakthrough Sends Biotech Stock Surging
10:04am, Wednesday, 14'th Dec 2022
Avidity Biosciences Inc (NASDAQ:RNA) is soaring this morning, after the biotech company shared positive data from a trial demonstrating the first-ever successful targeted delivery of RNA into musc
Avidity's stock rallies 39% on new RNA data
08:09am, Wednesday, 14'th Dec 2022
Shares of Avidity Biosciences Inc. RNA, -4.52% soared 39% in premarket trading on Wednesday after the company said its experimental RNA therapy, when injected into the muscle, has potential as a treat
Down 15.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Avidity Biosciences, Inc. (RNA)
10:40am, Friday, 18'th Nov 2022
The heavy selling pressure might have exhausted for Avidity Biosciences, Inc. (RNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall S
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue Estimates
07:33pm, Tuesday, 08'th Nov 2022
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 15.46% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s
Avidity (RNA) Down on Partial Hold of Myotonic Dystrophy Study
02:18pm, Wednesday, 28'th Sep 2022
Avidity Biosciences (RNA) reports FDA-imposed partial hold on enrolling new patients in its phase I/II MARINA study evaluating AOC 1001 in myotonic dystrophy type 1 in adults. Stock down.
